UBS Group Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $75.00

Gilead Sciences (NASDAQ:GILD) had its price target cut by equities research analysts at UBS Group from $81.00 to $75.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price target points to a potential upside of 12.06% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Mizuho dropped their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Royal Bank of Canada dropped their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 26th. Barclays dropped their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. Finally, Cantor Fitzgerald dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $84.71.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $66.93 on Wednesday. Gilead Sciences has a 52 week low of $66.89 and a 52 week high of $87.86. The stock has a market capitalization of $83.33 billion, a price-to-earnings ratio of 14.87, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. The firm has a 50-day simple moving average of $72.25 and a 200-day simple moving average of $76.66. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same quarter in the previous year, the business posted $1.67 earnings per share. Gilead Sciences’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences will post 6.55 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently modified their holdings of the business. Aviance Capital Partners LLC increased its stake in Gilead Sciences by 3.2% in the 1st quarter. Aviance Capital Partners LLC now owns 18,230 shares of the biopharmaceutical company’s stock valued at $1,335,000 after buying an additional 569 shares during the period. Mirador Capital Partners LP increased its stake in Gilead Sciences by 7.7% in the 1st quarter. Mirador Capital Partners LP now owns 11,997 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 853 shares during the period. LVW Advisors LLC increased its stake in Gilead Sciences by 56.4% in the 1st quarter. LVW Advisors LLC now owns 25,580 shares of the biopharmaceutical company’s stock valued at $1,874,000 after buying an additional 9,223 shares during the period. Roberts Wealth Advisors LLC acquired a new position in Gilead Sciences in the 1st quarter valued at $468,000. Finally, SteelPeak Wealth LLC increased its stake in Gilead Sciences by 19.5% in the 1st quarter. SteelPeak Wealth LLC now owns 112,617 shares of the biopharmaceutical company’s stock valued at $8,249,000 after buying an additional 18,349 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.